How to Evaluate Direct-to-Patient Healthcare and Pharmacy Platforms

Direct-to-patient programs have grown quickly. Several large manufacturers now offer direct programs, telehealth services prescribe and ship medicines, and online pharmacies compete on price and convenience. Patients face real choices, and brands face decisions about whether to partner with or build these platforms.

This guide groups the factors that matter. It does not rank specific platforms; offerings change often, and the right choice depends on the patient's condition, coverage, and needs.

Group 1: Clinical quality and safety

This group matters most.

• Real clinical evaluation. A licensed clinician reviews history and decides whether a medicine is appropriate, rather than a checkbox flow that always ends in a prescription.
• Follow-up care. Monitoring, lab work where needed, and a way to report side effects.
• Coordination. Ability to share records with the patient's regular doctor.
• Licensed pharmacy. Dispensing by a pharmacy licensed in the patient's state, with pharmacist access for questions.

Group 2: Access and cost transparency

• Clear prices before sign-up, including consultation, medicine, shipping, and subscription terms.
• Insurance options. Whether insurance can be used, and how cash prices compare.
• Cancellation terms that are easy to find and use.
• Supply reliability, especially for medicines with shortages.

Group 3: Information quality and balance

• Information about benefits and risks presented in a balanced way.
• No implication that a medicine is right for everyone.
• Clear distinction between promotional content and medical advice.

Regulators have paid more attention to how telehealth and DTP platforms advertise prescription drugs. In September 2025, FDA announced a broad enforcement push on drug advertising that included telehealth-related promotion. See telehealth advertising rules.

Group 4: Privacy and data use

• What health data is collected and why.
• Whether data is shared with advertisers or used for marketing, and how to opt out.
• Whether the platform is a HIPAA covered entity or relies on consumer privacy terms instead.
• How state health privacy laws are handled.

Group 5: Customer support and responsiveness

• How quickly patients can reach a person, including a clinician or pharmacist.
• Channels available: phone, chat, messaging.
• How problems with shipments, refills, and billing are resolved.
• Whether reviews and complaints show patterns.

Group 6: Ease of use and accessibility

• Simple sign-up and refill flows.
• Accessibility for people with disabilities, ideally following WCAG.
• Language options.
• Works on older devices and slower connections.

Using the framework as a brand

If a manufacturer is considering a DTP partner or building its own program, the same groups apply, plus:

• Promotional compliance for any brand content on the platform.
• Data flows between platform, brand, and partners.
• Measurement of starts and persistence through privacy-safe methods.
• Channel conflict with existing pharmacy and payer relationships.

The direct-to-patient pharma media article covers what DTP changes for media plans.

A simple scoring sheet

Common mistakes

• Choosing on price alone.
• Assuming every platform does a real clinical review.
• Ignoring how health data is used for marketing.
• Brands promoting platforms without reviewing how the platform presents the drug.

Practical takeaway

Whether you are a patient or a brand, check clinical quality and privacy first. A platform that is cheap and easy but skips real evaluation or shares health data loosely fails on the factors that matter most.

Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.